Melanoma Open House on May 24 At Moores UC San Diego Cancer Center

 

May 07, 2007  |  

Most people living in Southern California are familiar with skin cancer, but melanoma, its most deadly form, is not as well understood.  Prevention and diagnosis of melanoma are not clear-cut and the incidence and death rates are rising. Today melanoma affects one person in 34.

If you or someone you know has questions or concerns about melanoma, please plan to attend a free Melanoma Open House sponsored by the UC San Diego Moores Cancer Center from 6:30 to 8:30 p.m. Thursday, May 24.  Melanoma experts from the Cancer Center will share the latest information on prevention, detection, and medical and surgical therapies, and will answer questions.

Guests will also have the opportunity to use the “DermaScan” skin assessment device to view sun damage to their skin, which is often invisible to the naked eye.

The event will be held in the Goldberg Auditorium at the Center, 3855 Health Sciences Dr., La Jolla. Refreshments provided. Free parking. To attend, please call 858-822-6189 with name and the number attending.

This event is made possible with support from Schering-Plough, Novartis and UC San Diego.

# # #

Media Contact: Nancy Stringer, 619-543-6163,nstringer@ucsd.edu




Media Contact

Share This Article


Related News

7/20/2017
The Independent Citizens Oversight Committee of the California Institute for Regenerative Medicine (CIRM) today unanimously approved a $5.8 million award to University of California San Diego School o ...
7/10/2017
UC San Diego Health has been named one of the nation’s “Most Wired” health systems by Hospitals & Health Networks magazine, a publication of the American Hospital Association. The award recognizes hos ...
7/10/2017
Researchers at University of California San Diego School of Medicine have discovered differences in how the brain responds to food rewards in individuals with a history of bulimia nervosa (BN), an eat ...
7/5/2017
After 12 weeks of taking an anti-asthma drug, a subset of patients with type 2 diabetes showed a clinically significant reduction in blood glucose during a randomized, double blind, placebo-controlled ...



Follow Us